Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutic Pipeline Program, 2019
    Managing Levodopa-induced Dyskinesias by Targeting Dopamine D1 Receptor Signaling

    Study Rationale:
    Parkinson’s is a complex brain disease caused by the gradual loss of brain cells producing the neurotransmitter dopamine, which controls movement, emotion and affect. However...

  • Access to Data and Biospecimens, 2019
    Convergence of LRRK2 and GBA in the Pathogenesis of Parkinson’s Disease Supplement

    Promising Outcomes of Original Grant:
    In our original project we used dopamine cells derived from induced pluripotent stem cells (iPSCs) from people with Parkinson’s-associated LRRK2 or GBA mutations...

  • Therapeutic Pipeline Program, 2019
    Small Molecule Therapeutics Targeting Nurr1

    Study Rationale:
    Nurr1 is a protein that plays critical roles in the development, maintenance and survival of dopaminergic neurons and, as such, is a potential therapeutic target for treating the...

  • Target Advancement Program, 2019
    Investigating Vulnerability of Subsets of Dopaminergic Neurons

    Study Rationale:
    Brain cells that produce the neurotransmitter dopamine are the most vulnerable to cell death in Parkinson’s disease (PD), but the reasons for this are not known. New techniques have...

  • Research Grant, 2019
    Inhibition of LRRK2 Roc-COR GTPase

    Study Rationale:
    The LRRK2 protein is overactive in people with Parkinson’s and a mutation in the LRRK2 gene. Recent research shows LRRK2 may be overactive in a sporadic (cause unknown) Parkinson’s...

  • Therapeutic Pipeline Program, 2019
    Development of a Novel TRPML1 Activator for Parkinson’s Disease

    Study Rationale:
    A primary cause of Parkinson’s disease is build-up of a toxic protein in specific neurons in the brain. There is evidence that in Parkinson’s disease the cellular machinery to clear...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.